 Antonio Jimeno-Largo
| Title | Professor |
|---|
| Institution | University of Colorado Denver - Anschutz Medical Campus |
|---|
| Department | SOM-MED |
|---|
| Phone | 303/724-2478 |
|---|
|
|
|
 Research P50CA261605 (JIMENO, ANTONIO)Sep 1, 2021 - Aug 31, 2026 NIH
Colorado Head and Neck Cancer SPORE
Role: Principal Investigator |
| R01DE030683 (JIMENO, ANTONIO)Apr 1, 2021 - Mar 31, 2026 NIH
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
Role: Principal Investigator |
| T32CA236734 (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2025 NIH
Cancer Immunotherapy and Experimental Therapeutics - T32
Role: Principal Investigator |
| R01CA213102 (JIMENO, ANTONIO)Aug 1, 2017 - Jul 31, 2021 NIH
Development of an autologous humanized model of melanoma exploring human thymic education capacity
Role: Principal Investigator |
| R01DE024371 (WANG, XIAO-JING)Aug 1, 2014 - Jul 31, 2019 NIH
Identifying oral cancer stem cell properties affected by the microenvironment
Role: Co-Principal Investigator |
| R56DE023245 (REYLAND, MARY ELAINE)Sep 26, 2012 - Aug 31, 2015 NIH
Functional characterization of salivary gland cancers and development of patient
Role: Co-Principal Investigator |
| R21CA156114 (JIMENO, ANTONIO)Sep 8, 2011 - Aug 31, 2014 NIH
Rational combination of EGFR and Hedgehog inhibitors in head and neck cancer
Role: Principal Investigator |
| R01CA149456 (JIMENO, ANTONIO)Aug 9, 2010 - May 31, 2022 NIH
Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability
Role: Principal Investigator |
| R21DE019712 (JIMENO, ANTONIO)Sep 1, 2009 - Aug 31, 2012 NIH
Rational generation of a head and neck squamous cell cancer direct xenograft mode
Role: Principal Investigator |
Bibliographic
-
Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295. PMID: 36867316.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
|
Jimeno-Largo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|